Moderna to Present at Upcoming Investor Conferences

February 24, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 24, 2020-- Moderna, Inc. (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its participation in the following upcoming investor conferences:

- **Cowen and Company 40th Annual Health Care Conference** in Boston on Tuesday, March 3, 2020 at 11:20 a.m. ET.
- **Barclays Global Healthcare Conference** in Miami on Wednesday, March 11, 2020 at 9:30 a.m. ET.
- **Oppenheimer 30th Annual Healthcare Conference** in New York City on Tuesday, March 17, 2020 at 11:30 a.m. ET.

A live webcast of each presentation will be available under “Events and Presentations” in the Investors section of the Moderna website at [https://investors.moderna.com](https://investors.moderna.com). A replay of each webcast will be archived on Moderna’s website for 30 days following the presentation.

**About Moderna**

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators. Moderna has 24 mRNA development candidates in its portfolio across all modalities, with 12 in clinical studies. Four of these programs are in or preparing for Phase 2 studies and the Company is preparing for its first Phase 3 study.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca, Plc. (Nasdaq: AZN) and Merck, Inc. (Nasdaq: MRK), as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense; the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been named a top biopharmaceutical employer by Science for the past five years.


**Investors:**

Lavina Talukdar  
Head of Investor Relations  
617-209-5834  
Lavina.Talukdar@modernatx.com

Source: Moderna, Inc.